en · de · es · fr · pt
tb-500-notes.peptides8425.com › Faq › Thymosin Beta-4 Fragment Background — Reference Sheet

Thymosin Beta-4 Fragment Background — Reference Sheet

By Editorial Desk · published 2025-09-03 · last reviewed 2025-10-19 · Faq

This is a working overview of peptide fragment, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-10-19 and is reviewed periodically as new material appears.

Thymosin Beta-4 Fragment Background

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.

Handling, Storage, and Analytical Verification

Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.

The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.

Tb-500 at a glance

PropertyValueNotes
Molecular classSynthetic peptideN-terminal fragment of thymosin beta-4
Residue countSevenSequence LKKTETQ
Approximate mass889 DaAcetylated seven-residue peptide
Common synonymsTB4 fragment, TB500Not identical to full-length TB4
Reported activityActin bindingObserved mainly in cell-free systems

TB-500 Identity and Chemical Background

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Related pages on this site

Handling, Storage and Analytical Checks

Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.

Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.

Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.

Identification and Molecular Background

Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.

Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.

TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.

Further detail

== Ethics == AI has potential benefits and potential risks. AI may be able to advance science and find solutions for serious problems: Demis Hassabis of DeepMind hopes to "solve intelligence, and then use that to solve everything else". However, as the use of AI has become widespread, several unintended consequences and risks have been identified. In-production systems can sometimes not factor ethics and bias into their AI training processes, especially when the AI algorithms are inherently unexplainable in deep learning.

A study on the age of the carbonate thin layers covering or underlying rock art from the Cave of Altamira (Spain), providing evidence of several periods of cave art from the ceiling of the studied cave, is published by Pons-Branchu et al. (2026). Evidence from the Velika Pećina, Velika Vranovica and Pećina kod Stene cave sites (Serbia), indicative of human presence in central Balkans during the Last Glacial Maximum, is presented by Kuhn et al. (2026). Masojć et al. (2026) describe a Late Pleistocene human tooth from the Khutul Usny Cave site, representing the first fossil of an early Homo sapiens in Mongolia with secure geological context and providing evidence of presence of the species in southern Mongolia around the onset of the Last Glacial Maximum. A study on the frontal and mandibular morphology of the Red Deer Cave people, interpreted as consistent of affinities with Homo sapiens and indicative of diversity cranial morphology of late Pleistocene hominins from eastern Asia, is published by Fan et al. (2026). Evidence indicating that Solutrean artifacts from the Peña Capón rock shelter (Muriel-Tamajón, Spain) were sourced 600 to 700 kilometers away from this site, in the present-day territory of southwest France, is presented by Sánchez de la Torre et al. (2026). Nash et al. (2026) report rediscovery of putative Upper Paleolithic cave art from the Bacon Hole site (Wales, United Kingdom) originally discovered by William Sollas and Henri Breuil in 1912 and support the interpretation of the studied horizontal lines as cave art. Reiche et al.

This same proposal was proposed again in 1976, but further studies indicated that the recurrence rate was not better. In 1888, treatments were tried that entered the abdomen to make reattachments. Some did not agree with this and suggested an approach through the inguinal canal. In 1898, further abdominal approaches were proposed. No further advances have been noted until 1961 when reattachment of the anterior vaginal wall to Cooper's ligament began to be used. Unfortunately, posterior vaginal wall prolapse occurred in some patients even though the anterior repair was successful. In 1955, using mesh to support pelvic structures became common. In 1970, tissue from pigs began to be used to strengthen the anterior vaginal wall in surgery. Beginning in 1976, improvement in suturing began along with the surgical removal of the vagina being used to treat prolapse of the bladder. In 1991, assumptions about the detailed anatomy of the pelvic support structures began to be questioned regarding the existence of some pelvic structures and the non-existence of others. More recently, stem cells and robot-assisted laparoscopic surgery have been used to treat cystoceles.

are the respective mole fractions and viscosities of the component liquids. Since blending is an important process in the lubricating and oil industries, a variety of empirical and proprietary equations exist for predicting the viscosity of a blend.

== Research == Dietary BCAAs have been used in an attempt to treat some cases of hepatic encephalopathy. They can have the effect of alleviating symptoms of hepatic encephalopathy, but there is no evidence they benefit mortality rates, nutrition, or overall quality of life as further research is necessary. Certain studies suggested a possible link between a high incidence of amyotrophic lateral sclerosis (ALS) among professional American football players and Italian soccer players, and certain sports supplements including BCAAs. In mouse studies, BCAAs were shown to cause cell hyper-excitability resembling that usually observed in ALS patients. The proposed underlying mechanism is that cell hyper-excitability results in increased calcium absorption by the cell and thus brings about cell death, specifically of neuronal cells which have particularly low calcium buffering capabilities. Yet any link between BCAAs and ALS remains to be fully established. While BCAAs can induce a hyperexcitability similar to the one observed in mice with ALS, current work does not show if a BCAA-enriched diet, given over a prolonged period, actually induces ALS-like symptoms. Blood levels of the BCAAs are elevated in obese, insulin resistant humans and in mouse and rat models of diet-induced diabetes, suggesting the possibility that BCAAs contribute to the pathogenesis of obesity and diabetes. BCAA-restricted diets improve glucose tolerance and promote leanness in normal weight mice, restores insulin sensitivity and normal body weight to obese mice and promotes insulin sensitivity in obese rats.

Sources: en.wikipedia.org

Supporting material

Biko developed SASO's ideology of "Black Consciousness" in conversation with other black student leaders. A SASO policy manifesto produced in July 1971 defined this ideology as "an attitude of mind, a way of life. The basic tenet of Black Consciousness is that the Blackman must reject all value systems that seek to make him a foreigner in the country of his birth and reduce his basic human dignity." Black Consciousness centred on psychological empowerment, through combating the feelings of inferiority that most black South Africans exhibited. Biko believed that, as part of the struggle against apartheid and white-minority rule, blacks should affirm their own humanity by regarding themselves as worthy of freedom and its attendant responsibilities. It applied the term "black" not only to Bantu-speaking Africans, but also to Indians and Coloureds. SASO adopted this term over "non-white" because its leadership felt that defining themselves in opposition to white people was not a positive self-description. Biko promoted the slogan "black is beautiful", explaining that this meant "Man, you are okay as you are. Begin to look upon yourself as a human being." Biko presented a paper on "White Racism and Black Consciousness" at an academic conference in the University of Cape Town's Abe Bailey Centre in January 1971. He also expanded on his ideas in a column written for the SASO Newsletter under the pseudonym "Frank Talk".

== Overdose == Doses of methenamine much higher than usual have been clinically studied and found to produce significant toxicity. More specifically, doses of 8 g per day (4–8-fold usual doses) for 3 to 4 weeks resulted in bladder irritation, painful and frequent urination, albuminuria (albumin in urine), crystalluria (crystals in urine), and hematuria (blood in urine). Some of these side effects are thought to be due to high levels of formaldehyde in the bladder and consequent irritation. Doses of methenamine of up to 10 to 20 g/day have also been studied and found to be tolerable without major toxicity. When methenamine was first introduced in the late 1800s and early 1900s, doses of 15 to 30 g per day were commonly employed and doses of up to 60 to 180 g per day were tried in some cases. Toxic effects of such high doses included urinary tract and bladder irritation, frequent urination, strangury, and hematuria. Animal studies employing double the modern human dosage of methenamine for 6 to 12 months found no adverse effects.

== April 1942-May 1943 == The division was assigned to XXXXVIII Panzer Corps during the opening phases of Fall Blau (Case Blue), the Wehrmacht's 1942 strategic summer offensive in southern Russia. During the combined Soviet winter offensives Operation Uranus and Operation Mars in late November through mid-December, the division fought near Rzhev, where it was rendered combat ineffective. Called upon to deal with one crisis after another, the division came to be known as die Feuerwehr (the Fire Brigade). By 18 November 1942, the division only had seven Panzer II light tanks, one Panzer III and nineteen Panzer IV medium tanks, and three Sd.Kfz. 265 Panzerbefehlswagen command tanks operational. In January–February 1943, Großdeutschland and XXXXVIII Panzer Corps, along with the II SS Panzer Corps took part in the Third Battle of Kharkov. The division had 5 Panzer IIs, 20 Panzer IIIs, 85 Panzer IVs, 9 Tiger I heavy tanks, 2 Panzerbefehlswagens, and 26 Flammpanzer III flamethrower tank variants of the Panzer III available at that time. The division fought alongside the 1. SS Division Leibstandarte SS Adolf Hitler, 2. SS Division Das Reich and 3. SS Division Totenkopf during these battles. The division's losses as total write-offs at that time amounted to one Panzer III, twelve Panzer IVs, and one Tiger I. After the capture of Kharkov, the Großdeutschland was again pulled back and refitted.

=== Clinical trials === In addition to the increased production at the Dunn School, commercial production from a pilot plant established by Imperial Chemical Industries became available in January 1942, and Kembel, Bishop and Company delivered its first batch of 200 imperial gallons (910 L) on 11 September. Florey conducted a second series of clinical trials. Ethel was placed in charge, but while Florey was a consulting pathologist at Oxford hospitals and therefore entitled to use their wards and services, Ethel, to his annoyance, was accredited merely as his assistant. Doctors tended to refer patients to the trial who were in desperate circumstances rather than those who were the most suitable candidates for treatment, but when penicillin did succeed anyway, confidence in its efficacy rose. Harry Lambert, a friend of Fleming's dying from a meningococcal infection, became the twelfth case on 5 August 1942. He survived, but someone at St. Mary's Hospital leaked the result to the press, resulting in an editorial in The Times on 27 August. Florey was appalled; this could only create a public demand for penicillin when all available supplies were needed for the clinical trials. On 25 September, Florey met with Sir Cecil McAlpine Weir, the Director-General of Equipment and Stores at the Ministry of Supply, who promised overriding priority for the mass production of penicillin. Ethel and Howard Florey published the results of clinical trials of 187 cases of treatment with penicillin in The Lancet on 27 March 1943.

Altria, like other tobacco companies, has invested in science and medical companies which develop and produce medical products for conditions caused or aggravated by smoking. As of 2024, Altria's three medical subsidiaries included the following: Cronos group (maker of recreational cannabis), Lexaria Bioscience (Developer of proprietary drug delivery technology, DehydraTECH, to improve active pharmaceutical ingredients entrance into the bloodstream) and Micreos (biotech company focused on discovering and developing recombinant proteins for chronic dermatology and oncology conditions). It has also designed and marketed electronic cigarettes. Altria launched the MarkTen and Green Smoke brands. Both of these were discontinued in December 2018. The company returned to this market through the acquisition of NJOY.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.

What activity is attributed to this sequence?

The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.

Is there a standard purity specification?

Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.

Can the powder be stored at room temperature?

Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.

Network